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Abstract
Saprochaete capitata is yeast rarely causes human infections; none-
theless the vast majority of infections were reported in patients with 
hematological malignancy. Here, we report one of the unusually rare 
presentations of disseminated Saprochaete capitata in a patient with-
out hematological malignancy, but the patient had a prolonged his-
tory of chronic active hepatitis C, diabetes mellitus, prolonged ICU stay 
on mechanical ventilation, and exposure to several antimicrobials. The 
currently isolated Saprochaete capitata showed resistance to ampho-
tericin B, triazoles and ecchinocandins, but susceptible to 5-fluocyto-
cine with MIC ≤1 mg/dl. 
Keywords: Saprochaete capitata, hematological malignancy, yeast, an-
timicrobials exposure, antifungal resistance.
Introduction
Saprochaete capitata formerly called Geotrichum 
capitatum and Blastoschizomyces capitatus is re-
lated to fungi that rarely cause invasive human 
infections; when it does, usually in the immuno-
compromised individuals. Saprochaete capitata is 
widely spread in nature and can be isolated from 
soil, plants, water, and air. It can also be found in 
the digestive tract in humans and other mammals, 
and it may be found in food but never reported 
to cause disease through this route. The number 
of recorded Saprochaete capitata cases in English 
literature and related species so far are around 104 
cases [1, 2]. Disseminated Saprochaete capitata was 
reported in few case reports of single and five-case 
series, causing blood stream infection with severe 
sepsis syndrome, multi-organ failure, and mortality. 
Occasionally Saprochaete capitata is easily missed 
as Candida species for that they share the same 
epidemiology, the same predisposed host,and mor-
phologically somehow not apparently different [3, 
4, 5]. Uncommonly, a related species i.e.Geotrichum 
clavatum was also reported to cause disseminated 
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infections in few patients with acute myeloid leu-
kemia [6].
Saprochaete capitata breakthrough was also re-
ported in patients suffering from hematological 
malignancy while being treated with echinocandin 
therapy; caspofungin was the agent used in those 
reports [7, 8, 9]. As knowledge regarding this fun-
gus piles up, both fluconazole and ecchinocandins 
are recognized for being inadequate strategy as 
prophylactic or empirical antifungal treatment in 
patient with hematological malignancy when cases 
of Saprochaete capitata were found colonizing he-
matology unit and a potential threat to patients. 
Moreover, there is no consensus on the best anti-
fungal regimen to prescribe in disseminated disease 
as it is resistant to most antifungal agents in clinical 
use [4].
Case report
A 78 years old female patient, she was admitted on 
3 December 2014 to Al khalidi Hospital and Medi-
cal Centre, with the diagnoses of dementia, dia-
betes mellitus, and previously treated chronic HCV 
hepatitis. Eighteen months earlier she finished her 
pegylated interferon and ribavirin treatment. Her 
acute history dates back to five weeks when she 
was admitted to another general hospital not feel-
ing well with decreased appetite, she developed 
sudden onset of nausea and vomiting, few hours 
later she lost her consciousness and was intubated 
for respiratory difficulty. She was diagnosed as hav-
ing had an episode of diabetic ketoacidosis, spent 
more than two weeks in ICU and was managed 
to be extubated later. During her ICU stay she was 
treated as sepsis; suspected ventilator-associated 
pneumonia (VAP) due to Acinetobacter baumman-
ni, and she was started on meropenem and colistin 
for 14 days. Blood culture grew yeast which was not 
characterized then.
On arrival to our hospital she was in deep coma 
with breathing difficulty, no spontaneous move-
ments, puffy face, and mechanical ventilation was 
resumed; septic work up including blood cultures 
was commenced, she had pulmonary infiltrates that 
was progressively improving on daily radiological 
evaluation, with no stigmata of infective endocardi-
tis. Initial laboratory finding upon admission showed: 
WBC: 19.7K HB: 7.6, Platelets 60K, INR: 2.18. Blood 
film showed normochromic anisocytosis with mild 
rouleaux formation, WBC’s showed leucocytosis 
with neutrophilia, no immature cells seen, reduced 
platelets without clumps. Normal liver enzymes (ALT 
= 10 U/L and AST = 26 U/L), and normal liver ultra-
sound, abdominal CT scan showed “heterogeneous 
liver with spots of calcifications, no definite liver 
masses were detected”. 2D-echocardiography was 
normal. Brain CT showed no focal brain changes, 
but wide spread brain atrophy and de-pneumatized 
sphenoid sinus filled with fluid and mucosal swell-
ing. She was started on intravenous meropenem, 
four days later treatment with micafungin 100 mg/
day was added (weight = 75 Kg) when her aerobic 
blood cultures grew yeast, and it was evident from 
direct smear and gram-stained (Figure 1). After 43 
hours of incubation in BacT-ALERT (Biomerieux S.A. 
Chemin de I’Orme 69280. Marcy I’Etoile, FRANCE) 
the yeast was identified as Saprochaete capitata, 
then meropenem was discontinued. Subculture on 
Sabouraud dextrose agar plate grew in 24 hours, 
and was processed in VITEK II (Biomerieux S.A. Che-
min de I’Orme,69280. Marcy I’Etoile, FRANCE) using 
identification card. Susceptibility patterns showed 
resistance to the tested antifungals; amphotericinB 
(MIC ≥16 mg/dl), ecchinocandins (caspofungin MIC 
≥ 4 mg/dl, micafungin MIC ≥ 4 mg/dl), fluconazole 
(MIC ≥ 4 mg/dl) and voriconazole (MIC = 4 mg/dl) 
but 5-fluocytosine was susceptible (MIC ≤1 mg/dl). 
The patient died eleven days after her admission, 
and seven days of micafungin treatment.
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Discussion
Mazzocato and his coworkers reported in July 2014, 
their literature review between 1977 and August 
2013, they identified 104 cases of Saprochaete capi-
tata including their reported cases.They found that 
the patients’ median age was 56 years, 56% were 
males, and half of them had acute myeloid leuke-
mia, 22% with acute lymphoid leukemia, and 22% 
with other malignancies. The majority of patients 
(82%) were neutropenic at the time of diagnosis, 
and 75% of Saprochaete capitatawere isolated from 
blood. Mortality was about 60% and amphotericin 
was the mostly prescribed antifungal [2]. After their 
report, two cases were reported by other investiga-
tors as well as our current case [5, 7]. Our patient 
did not have hematological malignancy like earlier 
reports, rather diabetes mellitus and HCV hepati-
tis as comorbidities. Initially, elsewhere the fungus 
was described as yeast, possibly Candida, which 
may have not been an uncommon occurrence in 
many microbiological laboratories; in our hospital 
automated processing revealed the true nature of 
the yeast as Saprochaete capitata [4].
The patient presented to us in coma and looking 
severely ill, next day she needed ventilator support 
and vasopressors. She met her demise suffering 
from multiorgans dysfunction and failure. Here, 
Saprochaete capitata isolate was resistant to the 
tested antifungals, this agrees with the previously 
published literature from different authors that dis-
seminated infection with Saprochaete capitata is 
usually difficult to treat and carries high mortality 
[2, 7,8]. This is one of the rare cases of disseminated 
Saprochaete capitata in a patient without hemato-
logical malignancy; however the patient had a pro-
longed ICU stay, mechanical ventilation, and was 
exposed to several antibacterials, which are known 
risk factors for acquiring invasive candidiasis [10, 11]. 
Saprochaete capitata seemed to have smilar risk fac-
tors like invasive candidiasis. The patient was started 
on micafungin soon after blood culture revealed 
yeast; however it was too late for that she had previ-
ous untreated and persistent ‘yeast’ blood. infection 
[12]. It showed that starting antifungal therapy did 
not alter her expected poor prognosis though a re-
peat blood culture few days after antifungal therapy 
showed no growth of Saprochaete capitata or any 
other microorganism.
Figure 1. The appearance of Saprochaete capitata on gram stain (A), and on Muller-Hinton growth media (B).
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